Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 22
Encontrada(s) 1 página(s)

RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publicación Artículo científico (JournalArticle)

SARS-COV-2 viral RNA detection through oligonucleotide-capped nanoporous anodic alumina supports.

  • López-Palacios, Alba|||0000-0002-4397-277X
  • Caballos-Gómez, María Isabel
  • Hernández-Montoto, Andy|||0000-0001-5623-9836
  • Sancenón Galarza, Félix|||0000-0002-5205-7135
  • Martínez-Máñez, Ramón|||0000-0001-5873-9674
  • Aznar, Elena|||0000-0003-0361-3876
  • Aranda-Sobrino, María Nieves
  • Calbuig, Eva
  • Gómez-Ruiz, María Dolores
  • Tormo-Mas, M.A.
  • Peman, Javier
  • Climent Terol, Estela
[EN] We describe herein a sensor containing nanoporous anodic alumina (NAA) as sensing platform to identify SARSCOV-2 RNA using a gating mechanism. The system is based on NAA that contains a fluorescent dye (Rhodamine B; RhB) and is capped with an oligonucleotide sequence that hybridize specifically a region of SARS-CoV-2 genome. In the presence of RNA from SARS-COV-2 virus, the oligonucleotide of the surface is displaced, uncapping the pores, and producing a delivery of RhB. The detection of the virus is achieved measuring the fluorescence of the fluorophore. The nanosensor demonstrates to be highly sensitive and selective in aqueous buffers and in biological media, having a limit of detection (LOD) of 50 ± 30 copies mL-1 of SARS-CoV-2 RNA extracted from patients. Moreover, preliminary results using 18 real nasopharyngeal swab samples indicate the potential of the system to differentiate between infected and non-infected patients. Compared to the conventional RT-PCR method, in our system there is no need for sample pretreatment or RNA isolation, providing diagnostic outcomes within 60 mins while maintaining a high level of reliability, This study was sponsored by the Spanish Government (projects PID2021-126304OB-C41 (DOROTHY), PID2021-128141OB-C22 (ANTIVIBEM), and PID2021-122875OB-100 (MCUI/AEI/ FEDER, UE)), the Generalitat Valenciana (project no.2 RD 180/2020, CIPROM/ 2021/007), Supera COVID-19 Fund (DIACOVID project), the Universitat Polit`ecnica de Val`encia− Instituto de Investigacion ¿ Sanitaria La Fe (IISLaFe) (SARS-COV-2-SEEKER and VISION-COV projects). This research project has received funding from the European Union s HORIZON-CL4- 2022 research and innovation programme under grant agreement ID 101093042, PHOTONGATE project. Funded by the European Union. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union or European Research Council. Neither the European Union nor th e granting authority can be held responsible for them. This work was supported by the European Research Council (ERC) via Advanced Grant (101052997, EDISON). Also, the project has received funding from the European Union s HORIZON-CL4-2022 research and innovation programme under grant agreement ID 101093042, PHOTONGATE project. A.L.P. thanks the Ministerio de Universidades for his predoctoral grant (FPU20/05297). E. C. thanks the Instituto de Salud Carlos III (Miguel Servet 2023 CP23/00086). Scheme 1 was done with BioRender.com. The Medicaments Research Ethics Committee, CEIm of University and Polytechnic La Fe Hospital of Valencia (2021-012-1) approved the use of samples from human patients.
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publicación Artículo científico (JournalArticle)

Targeted detection of Mycobacterium tuberculosis MPT64 antigen using an antibody-coated nanoporous anodic alumina biosensor: A novel approach for tuberculosis screening

  • Caballos, Isabel
  • Climent Terol, Estela
  • Gil-Brusola, Ana
  • Hernández-Montoto, Andy|||0000-0001-5623-9836
  • Martínez-Máñez, Ramón|||0000-0001-5873-9674
  • Aznar, Elena|||0000-0003-0361-3876
[EN] Tuberculosis (TB) is a chronic condition caused by Mycobacterium tuberculosis. According to WHO's Global Tuberculosis Report 2024, TB has again become the leading cause of death from a single infectious agent, surpassing COVID-19 in 2023 and 2024 in terms of infectious disease deaths. Due to its high infectivity and serious effects, timely diagnosis and treatment are crucial for controlling its spread. This study presents a fluorogenic biosensor for detecting M. tuberculosis MPT64 antigen using gated nanoporous anodic alumina (NAA). NAA material is loaded with rhodamine B and capped with an antibody against MPT64 protein. The presence of MPT64 induces antibody displacement due to the specific recognition and subsequent release of rhodamine B to the medium that is detected by fluorescence measurement. The biosensor is physicochemically characterized by scanning electron microscopy and X-ray spectroscopy. The biosensor achieves a limit of detection (LOD) of 1.32 nM (0.032 mg L-1) for MPT64 protein and demonstrated high selectivity through testing against various antigens from other viral pathogens and bacterial species. The efficacy of the biosensor is further validated with grown mycobacteria from clinical samples. The developed approach offers three key aspects: (i) selective detection of active TB by targeting the secreted MPT64 protein using gated nanomaterials; (ii) a rapid response (60 min); and (iii) a cost-effective design suitable for resource-limited settings. This biosensor shows great potential as a tool for the clinical diagnosis of active tuberculosis., We thank PID2024-155683OB-C41 and PID2021-126304OB-C41 from the Ministerio de Ciencia, Innovacion y Universidades and AEI/10.13039/501100011033 (co-financed by the European Regional Development Fund) , and CIPROM/2021/007 (to R. M.-M.) from the Generalitat Valenciana. This research was also supported by CIBER, Instituto de Salud Carlos III (group CB07/01/2012) . I.-C. thanks the Instituto de Salud Carlos III for her predoctoral fellowship (IFI21/00008) . We thank electron microscopy service of UPV for their support. R.M.M. thanks to the European Union's Horizon EUROPE research and innovation programme under grant agreement No 101093042. E. C. thanks the Instituto de Salud Carlos III for funding the proyects Miguel Servet 2023 CP23/00086 and PI24_01239, both co-funded by the European Union.
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publicación Artículo científico (JournalArticle)

Anthracene-Modified Nanoporous Silica Nanoparticles for ATP Detection and Salivary Diagnostics in Parkinson&apos, s Disease

  • Ahi, E.E.
  • Climent Terol, Estela
  • Beyret, Cansu
  • Caglayan, Mehmet Gokhan
  • Coban, Burak
  • Yilmaz, Rezzak
  • Durmus, Mahmut
  • Martí-Centelles, Vicente|||0000-0002-9142-9392
  • Martínez-Máñez, Ramón|||0000-0001-5873-9674
[EN] ATP is an essential biological molecule, and abnormal levels are linked to various diseases. In this study, we developed an optical sensor array consisting of an anthracene-modified MCM-41 mesoporous nanoparticle-based hybrid organic-inorganic material to detect ATP in a TRIS-HCl buffer (pH 7). To create the sensor, we synthesized MCM-41 silica nanoparticles and functionalized them with aminoanthracene and imidazolium-anthracene groups. The fluorescence responses of the optical sensor array were recorded and analyzed by using a pattern recognition protocol, specifically linear discriminant analysis, to distinguish between ATP, ADP, AMP, and potential interferents. Quantitative regression analysis of ATP in TRIS-HCl was performed using artificial neural networks, which yielded an acceptable error rate of 7.8%. The sensor array was also evaluated for discrimination of Parkinson's disease (PD) from healthy controls, based on pattern recognition of ATP-related analytes in saliva samples from 24 patients with PD and 23 healthy controls. The results showed that the MCM-41 mesoporous silica nanoparticle-based sensor array can discriminate PD by pattern recognition with 73.7% sensitivity and 83.3% specificity., The diagnostic part of this study is supported by the Ankara University Scientific Research Projects Coordination Office (TSA-2023-2648 and TSA-2025-3825). V.M.-C. acknowledges financial support from the Project CIDEGENT/2020/031 funded by the Generalitat Valenciana, Project ESGENT/2024/ 001 funded by the Generalitat Valenciana, project PID2024- 157188OB-I00 funded by MICIU/AEI/10.13039/ 501100011033 and FEDER A way to make Europe, project PID2020-113256RA-I00 funded by MICIU/AEI/10.13039/ 501100011033, and project CNS2023-144879 funded by MICIU/AEI/10.13039/501100011033 and European Union NextGenerationEU/PRTR. R.M.-M. acknowledges the European Union s Horizon EUROPE research and innovation program under grant agreement no. 101093042, project PID2024-155683OB-C41 funded by MICIU/AEI/10.13039/ 501100011033 and FEDER A way to make Europe, project PID2021-126304OB-C41 funded by MICIU/AEI/10.13039/ 501100011033 and FEDER A way to make Europe, and project PROMETEO CIPROM/2021/007 funded by Generalitat Valenciana. E.C. thanks the Instituto de Salud Carlos III for founding the projects Miguel Servet 2023 CP23/00086 and PI24_01239, both cofunded by the European Union.
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publicación Artículo científico (JournalArticle)

SARS-CoV-2 N protein IgG antibody detection employing nanoporous anodized alumina: A rapid and selective alternative for identifying naturally infected individuals in populations vaccinated with spike protein (S)-based vaccines

  • Esteve-Sánchez, Yoel|||0000-0002-6845-1110
  • Hernández-Montoto, Andy|||0000-0001-5623-9836
  • Marcos Martínez, María Dolores|||0000-0001-7079-8589
  • Martínez-Máñez, Ramón|||0000-0001-5873-9674
  • Aznar, Elena|||0000-0003-0361-3876
  • Tormo-Mas, M.A.
  • Peman, Javier
  • Eva Calbuig
  • Gomez, Maria Dolores
  • Climent Terol, Estela
[EN] Methods to detect naturally infected individuals, especially during or after a pandemic, are valuable in populations with a high rate of vaccination. Having in mind that after the COVID-19 pandemic people has been vaccinated against the virus by Spike protein (S)-based vaccines, we present in this paper a novel nanosensor based on gated nanoporous anodic alumina (NAA) material to detect naturally infected individuals in populations with high rates of vaccination. The nanosensor developed is based on a protein-capped nanomaterial for the identification of IgG antibodies that can detect nucleocapsid protein (N) of SARS-CoV-2. The NAA material has been loaded with an indicator (Rhodamine B (RhB)) and the pores of the material have been blocked with SARS-CoV-2 nucleocapsid protein (N) attached to a specific aptamer. In presence of antibodies against this antigen, the pores are uncapped, triggering the dye release and a fluorescent signal as a result. The biosensor has been tested in vitro and simulated serum for IgG detection, proving a detection limit of 1 mu g/mL. Moreover, specificity assays with N proteins from other coronaviruses have proved the robustness and efficacy of this nanosensor. Finally, the system has been tested on samples from patients that contained SARS-CoV-2 antibodies, demonstrating its potential for the discrimination of individuals that have been vaccinated or infected by SARS-CoV-2 virus., This research was supported by projects PID2021-126304OB-C41, PID2021-128141OB-C22, and PID2021-122875OB-100 funded by MCIN/AEI/10.13039/501100011033/and by European Regional Development Fund-A way of doing Europe. This work was also funded by the Generalitat Valenciana (project no.2 RD 180/2020, CIPROM/2021/007) , Santander and CRUE Supera COVID-19 Fund (DIACOVID project) , the Universitat Politecnica de Valencia-Instituto de Investigacion Sanitaria La Fe (IIS-LaFe) (SARS-COV-2-SEEKER and VISION-COV projects) . R.M thanks to the European Union's Horizon EUROPE Research and Innovation Program (grant agreement No 101093042) . Y.E.-S. acknowledges the Ministerio de Universidades for his predoctoral grant (FPU20/05297) . E.C. thanks the Instituto de Salud Carlos III (Miguel Servet 2023 CP23/00086) . Scheme 1 done with BioRender.com . The use of clinical samples from patients was approved by the Drug Research Ethics Committee, CEIm of Hospital Universitari i Politecnic La Fe of Valencia (2021-012-1) . In all cases was obtained an informed oral consent from all participants or next of kin prior to the research.r E.-S. acknowledges the Ministerio de Universidades for his predoctoral grant (FPU20/05297) . E.C. thanks the Instituto de Salud Carlos III (Miguel Servet 2023 CP23/00086) . Scheme 1 done with BioRender.com . The use of clinical samples from patients was approved by the Drug Research Ethics Committee, CEIm of Hospital Universitari i Polite`cnic ` cnic La Fe of Valencia (2021-012-1) . In all cases was obtained an informed oral consent from all participants or next of kin prior to the research.
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publicación Artículo científico (JournalArticle)

Test Strips Based on Gated Nanoporous Anodic Alumina for the Rapid and Accurate Detection of Pseudomonas aeruginosa in Clinical Samples

  • Torres-Mesado, Andrea
  • Patricia Bernabé-Quispe
  • Tormo-Mas, María Ángeles
  • Pemán, Javier
  • Climent Terol, Estela
  • Caballos-Gómez, María Isabel
  • López-Palacios, Alba|||0000-0002-4397-277X
  • Hernández-Montoto, Andy|||0000-0001-5623-9836
  • Aznar, Elena|||0000-0003-0361-3876
  • Martínez-Máñez, Ramón|||0000-0001-5873-9674
[EN] Pseudomonas aeruginosa is a high-priority pathogen responsible for up to 23% of infections in intensive care units, yet current diagnostic methods remain hindered by multiday delays or high technical complexity. In this study, we report a rapid and highly sensitive biosensor based on nanoporous anodic alumina (NAA) capped with a specific oligonucleotide molecular gate targeting the phzA2 gene. The S3 biosensor achieved a limit of detection (LOD) of 0.153 ng mu L-1 for genomic DNA and an exceptional 28 CFU mL(-1) for direct bacterial detection without the need for prior DNA extraction. Validation in 63 clinical urine samples demonstrated a sensitivity of 91.67% and a specificity of 94.87% (AUC: 0.961, p-value < 0.0001). Furthermore, the sensor was integrated into Lateral Flow Assay (LFA), enabling the discrimination of positive and negative clinical samples in only 1 min with 100% specificity and 90.9% sensitivity. These results, combined with a one-year stability at 4 degrees C, position this gated-nanodevice as a robust and low-cost tool for Point-of-care (POC) diagnosis of P. aeruginosa infections., This research was funded by projects PID2024-155683OB-C41, PID2021-126304OB-C41, PID2021-122875OB-I00, and TED2021-132114B-100, supported by MCIN/AEI/10.13039/501100011033, the European Regional Development Fund, the European Union (NextGenerationEU/PRTR), and the Generalitat Valenciana (CIPROM/2021/007). This study is part of the Advanced Materials programme (MFA/2022/053) and was supported by MCIN with funding from the European Union's NextGenerationEU (PRTR-C17. I1) and by the Generalitat Valenciana. The project was also funded by Ayuntamiento de Valencia (SPI2024-096) and Instituto de Salud Carlos III (PI24/01239), cofunded by the European Union. In the same way, A.T. would like to thank the INVESTIGO program of the Ministry of Innovation, Universities, Research, and Digital Society of the Valencian Community for offering this research opportunity (INVEST/2023/443). To conclude, A.T. is grateful to the Asociacion Espanola Contra el Cancer for her 2024 predoctoral fellowship (PRDVA246577TORR (2024-0590-1)), which enabled this research. E.C. thanks the Instituto de Salud Carlos III (Miguel Servet 2023 CP23/00086), cofounded by the European Union. The authors thank Electron Microscopy Service at UPV for support. Funding for open access charge: CRUE-Universitat Politecnica de Valencia.
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publicación Artículo científico (JournalArticle)

Molecular Cages as Probes in Indicator Displacement Assays: The Case of Scopolamine Detection

  • Montà-González, Giovanni|||0000-0002-0739-9937
  • Garrido-García, Eva María
  • Martínez-Máñez, Ramón|||0000-0001-5873-9674
  • Martí-Centelles, Vicente|||0000-0002-9142-9392
  • Climent Terol, Estela
  • Vicent, Cristian
[EN] A study of the Pd-based molecular cage C1 host-guest properties against fluorescein and the drug scopolamine is reported. C1 forms an interpenetrated structure C12 in the presence of >= 40% water in H2O/DMSO solvent mixtures. The presence of fluorescein (FL) induces the disassembly of the C12 structure to form the [FL2 subset of C1] complex. Moreover, the addition of scopolamine (SCOP, a drug typically involved in drug-facilitated sexual assaults) to [FL2 subset of C1] results in fluorescein release and the formation of [SCOP subset of C12], obtaining a fluorescence signal proportional to the concentration of scopolamine with a limit of detection as low as 59.4 mu g mL-1. A good selectivity for scopolamine against other drugs such as MDMA, cocaine, GBL, and ketamine is observed. This is the first scopolamine detection method described to date using a molecular cage and one of the very few examples of the use of cages in indicator displacement assays. Similar concepts could be applied to the design of other molecular cage-based sensors for the detection of target analytes., V.M.-C. acknowledges the financial support from projects ESGENT/2024/001 and CIDEGENT/2020/031, both funded by the Generalitat Valenciana, Project PID2024-157188OB-I00 funded by MICIU/AEI/10.13039/501100011033 y FEDER A way to make Europe, Project PID2020-113256RA-I00 funded by MICIU/AEI/10.13039/501100011033, and Project CNS2023-144879 funded by MICIU/AEI/10.13039/501100011033 and European Union NextGenerationEU/PRTR. R.M.- M. acknowledges the financial support from Project PROMETEO CIPROM/2021/007 from the Generalitat Valenciana, project PID2024-155683OB-C41 funded by MICIU/AEI/10.13039/501100011033 y FEDER A way to make Europe, and project PID2021-126304OB-C41 funded by MICIU/AEI/10.13039/501100011033/and FEDER A way to make Europe. This research was supported by CIBER Consorcio Centro de Investigacion Biomedica en Red (CB06/01/2012), Instituto de Salud Carlos III, Ministerio de Ciencia e Innovacion. E.C. thanks the Instituto de Salud Carlos III (Miguel Servet 2023 CP23/00086) and E.G. is grateful to the Spanish MIU and European Union-Next Regeneration EU for her "Margarita Salas" postdoctoral grant (UP2021-036). The authors would like to acknowledge the Rigel computing system of the Universitat Politecnica de Valencia for providing the computational resources necessary for this study. The authors thank the U26 facility of ICTS "NANBIOSIS" and the nuclear magnetic resonance facility of Fundacion de la Comunidad Valenciana Centro de Investigacion Principe Felipe (CIPF) for NMR experiments. The authors thank "Servei Central d'Instrumentacio Cientifica (SCIC)" at Universitat Jaume I for mass spectrometry measurements.
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publicación Artículo científico (JournalArticle)

Chemical Communication between Giant Vesicles and Gated Nanoparticles for Strip-Based Sensing

  • Ventura-Cobos, Jordi|||0000-0001-8475-9820
  • Martínez-Máñez, Ramón|||0000-0001-5873-9674
  • Llopis-Lorente, Antoni|||0000-0002-6987-9506
  • Climent Terol, Estela
[EN] Inspired by nature, the development of artificial micro/nanosystems capable of communicating has become an emergent topic in nanotechnology, synthetic biology, and related areas. However, the demonstration of actual applications still has to come. Here, we demonstrate how chemical communication between micro- and nanoparticles can be used for the design of sensing systems. To realize this, we synergistically combine two different types of particles: i.e., giant unilamellar vesicles (GUVs) as senders and gated mesoporous nanoparticles as receivers. The use of engineered GUVs allows the detection of analytes based on responsive membranes, while the use of gated nanoparticles allows a straightforward application on test strips with smartphone-based detection. In addition, we demonstrate that the combined communication system exhibits signal amplification and its application in real samples employing the bacterial toxin ¿-hemolysin as target analyte. Altogether, our report presents a new route for engineering sensing systems based on the combination of communicative micro/nanoparticles., The authors would like to acknowledge the support from ERC Advanced Grant Edison (101052997); the Spanish Ministry of Science and Innovation, AEI, and FEDER-EU (project PID2021-126304OB-C41), and the GVA (Project CIPROM/2021/007). A.L.-L. thanks the Spanish Government for his "Ramon y Cajal" Fellowship (RYC2021-034728-I), funded by MCIN/AEI/10.13039/501100011033 and by the European Union "NextGenerationEU" / "PRTR". A.L-L. also thanks the UPV for funding (Ayuda para potenciar la investigacion postdoctoral de la UPV (PAID-PD-22), Ayuda a Primeros Proyectos de Investigacion (PAID-06-22), Vicerrectorado de Investigacion de la Universitat Politecnica de Valencia (UPV)). E.C. thanks the Instituto de Salud Carlos III for her Miguel Servet Fellowship (CP23/00086).
Minerva. Repositorio Institucional de la Universidad de Santiago de Compostela
Publicación Artículo científico (JournalArticle)

DNA methylation signatures of severe RSV infection in infants: evidence from non-invasive saliva samples

  • Pischedda, Sara
  • Gómez Carballa, Alberto
  • Pardo Seco, Jacobo José
  • Viz Lasheras, Sandra
  • Camino Mera, Alma
  • Bello, Xabier
  • Currás Tuala, María José
  • Rivero Calle, I.
  • Dacosta Urbieta, A. I.
  • Martinón Torres, Federico
  • Salas Ellacuriaga, Antonio
  • GENDRES Consortium
Background: Respiratory syncytial virus (RSV) poses significant morbidity and mortality risks in childhood, particularly for previously healthy infants admitted to hospitals lacking predisposing risk factors for severe disease. This study aimed to investigate the role of the host epigenome in RSV infection severity using non-invasive buccal swabs from sixteen hospitalized infants admitted to the hospital for RSV infection. Eight patients had severe symptoms, and eight had mild to moderate symptoms. For DNA methylation analyses, the Illumina EPIC BeadChip was used with DNA isolated from saliva samples. To evaluate the basal DNA methylation level of the identified biomarkers a cohort of healthy control children was used. Furthermore, DNA methylation levels of candidate genes were confirmed by pyrosequencing in both the discovery and validation cohorts of patients with mild to moderate symptoms. Results: A panel of differentially methylated positions (DMPs) distinguishing severe from mild to moderate symptoms in infants was identified. DMPs were determined using a threshold of an adjusted P-value (false discovery rate, FDR) < 0.01 and an absolute difference in DNA methylation (delta beta) > 0.10. Differentially methylated regions (DMRs) were identified in the ZBTB38 (implicated in asthma and pulmonary disease) and the TRIM6-TRM34 gene region (associated with viral infections). The differential DNA methylation of these genes was validated in an independent replication cohort. A weighted correlation network analysis emphasized the pivotal role of a module with RAB11FIP5 as the hub gene, known for its critical function in regulating viral infections. Conclusions: Oral mucosa methylation may play a role in determining the severity of RSV disease in infants.
RUA. Repositorio Institucional de la Universidad de Alicante
Publicación Otros (Other)

The Influence of Hospitalization and Nursing Interventions on Inpatients' Sleep Quality: A Multicenter Observational Study

  • Bellon, Filip
  • Targa, Adriano
  • Perez-Loza, Isabel
  • Abad Corpa, Eva
  • Rubinat-Arnaldo, Esther
  • Orts-Cortés, María Isabel
  • Gea-Sánchez, Montse
  • Orts-Cortés, María Isabel|||/items/836e2e92-e1ca-4454-8889-fcc3a4034e0e
Background: Sleep quality is a critical component of health and recovery, yet it remains a significant challenge during hospitalization. Poor sleep among inpatients is common and worsens throughout hospital stays, adversely affecting health outcomes and patient wellbeing. Despite its importance, sleep often receives limited attention within hospital policies and nursing practices. Aim: To evaluate the impact of hospitalization and night-time nursing interventions on the sleep quality of noncritical patients in Spanish public hospitals. Methods: An observational, multicenter study was conducted across 12 public hospitals. Data were collected from patients admitted to surgical and medical units between January 2020 and February 2022. Sleep quality was assessed using the Pittsburgh Sleep Quality Index at hospital admission and discharge. Night-time nursing interventions (including medication administration, vital signs monitoring, blood sample collection, and anxiety management interventions), sociodemographic, anthropometric, clinical variables, and self-reported disturbances were also recorded. Statistical analyses included descriptive statistics and linear regression models adjusted for potential confounding factors. Results: The study included 383 patients. Most patients (71%) presented poor sleep quality upon admission, which worsened during hospitalization (85.9%). A significant association was found between the number of intervention days and poorer sleep quality. Collection of blood samples was significantly associated with worsened sleep quality in female patients, while anxiety management was associated with lower sleep quality in males. Discomfort with roommates and night-time nursing interventions were also related to worse sleep quality. Linking Evidence to Action: Hospitalization exacerbates poor sleep quality in noncritical patients. Night-time nursing interventions, discomfort with the hospital environment, and anxiety management are key factors. Interventions addressing these modifiable factors could improve patients' sleep quality and recovery. Hospital policies should incorporate sleep as a key quality indicator, promoting strategies to reduce unnecessary night-time interventions and environmental disturbances. Nursing education must emphasize sleep-friendly care practices and appropriate planning of night-time activities.
RUC. Repositorio da Universidade da Coruña
Publicación Artículo científico (JournalArticle)

GUANIN: an all-in-one GUi-driven analyzer for NanoString interactive normalization

  • Montoto Louzao, Julián
  • Gómez-Carballa, Alberto
  • Bello, Xabier
  • Pardo-Seco, Jacobo
  • Camino-Mera, Alba
  • Viz-Lasheras, Sandra
  • Martín, María J.
  • Martinon-Torres, Federico
  • Salas, Antonio
GUANIN can be installed with pip install GUANIN and it is available at https://pypi.org/project/guanin/. Source code, documentation, and case studies are available at https://github.com/julimontoto/guanin under the GPLv3 license., [Abstract]: Most tools for normalizing NanoString gene expression data, apart from the default NanoString nCounter software, are R packages that focus on technical normalization and lack configurable parameters. However, content normalization is the most sensitive, experiment-specific, and relevant step to preprocess NanoString data. Currently this step requires the use of multiple tools and a deep understanding of data management by the researcher. We present GUANIN, a comprehensive normalization tool that integrates both new and well-established methods, offering a wide variety of options to introduce, filter, choose, and evaluate reference genes for content normalization. GUANIN allows the introduction of genes from an endogenous subset as reference genes, addressing housekeeping-related selection problems. It performs a specific and straightforward normalization approach for each experiment, using a wide variety of parameters with suggested default values. GUANIN provides a large number of informative output files that enable the iterative refinement of the normalization process. In terms of normalization, GUANIN matches or outperforms other available methods. Importantly, it allows researchers to interact comprehensively with the data preprocessing step without programming knowledge, thanks to its easy-to-use Graphical User Interface (GUI)., The supercomputer FinisTerrae III and its permanent data storage system have been funded by the Spanish Ministry of Science and Innovation, the Galician Government, and the European Regional Development Fund (ERDF). This study also received support by (i) ISCIII: TRINEO: PI22/00162; DIAVIR: DTS19/00049; Resvi-Omics: PI19/01039 (A.S.), ReSVinext: PI16/01569, Enterogen: PI19/01090 (F.M.-T.), cofinanciados FEDER, (ii) GAIN: IN607B 2020/08 and IN607A 2023/02 (A.S.), GEN-COVID: IN845D 2020/23 (F.M.-T.), IIN607A2021/05 (F.M.-T.); (iii) ACIS: BI-BACVIR (PRIS-3, to A.S.), CovidPhy (SA 304 C, to A.S.); and (iv) consorcio Centro de Investigación Biomédica en Red de Enfermedades Respiratorias (CB21/06/00103; to A.S. and F.M.-T.). In addition, this study has been funded by ISCIII through the project “CP23/00080” and co-funded by the European Union. The funders were not involved in the study design, collection, analysis, interpretation of data, the writing of this article, or the decision to submit it for publication., Xunta de Galicia; IN607B 2020/08, Xunta de Galicia; IN607A 2023/02, Xunta de Galicia; IN845D 2020/23, Xunta de Galicia; IIN607A2021/05, Centro de Investigación Biomédica en Red de Enfermedades Respiratorias; CB21/06/00103
DAU Arxiu Digital de la Universitat Ramon Llull
Publicación Artículo científico (JournalArticle)

Concurrence of FGFR1 mutations modulates oncogenesis in glioneuronal tumors

  • Boni, Jacopo
  • Fernández-González, Míriam
  • Han, HyeRim
  • Roca, Carla
  • Wong, Cassandra
  • Rioja, Cristina
  • Nogué i Ansón, Clara
  • MANEN-FREIXA, LETICIA
  • Boulais, Jonathan
  • Torres-Urtizberea, Endika
  • Gomez Moruno, Antonio
  • Hasselblatt, Martin
  • Estrada-Tejedor, Roger
  • Antolin, Albert A.
  • Elkholi, Islam
  • Jabado, Nada
  • Côté, Jean-François
  • Gingras, Anne-Claude
  • Rivera, Barbara
FGFR1 genetic alterations are associated with brain malignancies, including FGFR1 mutations in familial and sporadic cases of low-grade glioneuronal tumors, suggesting intrinsic mechanisms of selective pressure toward FGFR1 multiple events arising in the context of a quiet genome. To decipher the molecular mechanisms triggered by multiple concurrent FGFR1 mutations, we have mapped the proximal interactome of wild-type, single- and double-mutant FGFR1 proteins through a BioID-MS approach. Our data reveal novel oncogenic functionality for the two hotspot mutations N546K and K656E, linked to evasion of lysosomal degradation. Further, we identified a modulatory tumor-suppressive role for the susceptibility variant R661P, which hampers the oncogenic potential of both hotspot N546K and K656E mutations by rescuing receptor degradation and reducing N546K affinity for the downstream effector PLCγ. Introducing the R661P missense variant was sufficient to abolish self-renewal capacity of oligodendroglioma cells and downregulate genes involved in neurodevelopment and neuro-glial cell fate decisions, both aspects overcome in the double mutants. This study sheds light on contextual oncogenic effects associated with FGFR1 alterations and their recurrence in low-mutation burden and therapy naive tumors., info:eu-repo/semantics/publishedVersion
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Increased hepatic putrescine levels as a new potential factor related to the progression of metabolic dysfunction-associated steatotic liver disease

  • Núñez-Sánchez, María Ángeles
  • Martínez-Sánchez, María Antonia
  • Sierra-Cruz, Marta
  • Lambertos, Ana
  • Rico-Chazarra, Sara
  • Oliva-Bolarín, Alba
  • Balaguer-Román, Andrés
  • Yuste, Jose E.
  • Martínez, Carlos Manuel
  • Mika, Adriana
  • Frutos, María Dolores
  • Llamoza-Torres, Camilo J.
  • Córdoba-Chacón, José
  • Ramos-Molina, Bruno
Metabolic dysfunction-associated steatotic liver disease (MASLD) is a chronic liver condition that often progresses to more advanced stages, such as metabolic dysfunction-associated steatohepatitis (MASH). MASH is characterized by inflammation and hepatocellular ballooning, in addition to hepatic steatosis. Despite the relatively high incidence of MASH in the population and its potential detrimental effects on human health, this liver disease is still not fully understood from a pathophysiological perspective. Deregulation of polyamine levels has been detected in various pathological conditions, including neurodegenerative diseases, inflammation, and cancer. However, the role of the polyamine pathway in chronic liver disorders such as MASLD has not been explored. In this study, we measured the expression of liver ornithine decarboxylase (ODC1), the rate-limiting enzyme responsible for the production of putrescine, and the hepatic levels of putrescine, in a preclinical model of MASH as well as in liver biopsies of patients with obesity undergoing bariatric surgery. Our findings reveal that expression of ODC1 and the levels of putrescine, but not spermidine nor spermine, are elevated in hepatic tissue of both diet-induced MASH mice and patients with biopsy-proven MASH compared with control mice and patients without MASH, respectively. Furthermore, we found that the levels of putrescine were positively associated with higher aspartate aminotransferase concentrations in serum and an increased SAF score (steatosis, activity, fibrosis). Additionally, in in vitro assays using human HepG2 cells, we demonstrate that elevated levels of putrescine exacerbate the cellular response to palmitic acid, leading to decreased cell viability and increased release of CK-18. Our results support an association between the expression of ODC1 and the progression of MASLD, which could have translational relevance in understanding the onset of this disease. © 2024 The Pathological Society of Great Britain and Ireland, We are particularly grateful for the generous contribution of the patients and the collaboration of Biobank Network of the Region of Murcia, BIOBANC-MUR, registered on ‘Registro Nacional de Biobancos’ with registration number B.0000859. BIOBANC-MUR was supported by the ‘Instituto de Salud Carlos III (proyecto PT20/00109)’, by ‘Instituto Murciano de Investigación Biosanitaria, IMIB’ and ‘Consejería de Salud de la Comunidad Autónoma de la Región de Murcia’. Research reported in this publication was supported by the National Institute of Diabetes and Digestive and Kidney Diseases of the National Institutes of Health (NIH) (awards numbers R01DK131038, R03DK129419) and by the Institute of Health Carlos III (ISCIII) (award numbers PI20/00505 and PI23/00171). MÁNS is supported by the ‘Miguel Servet’ program (CP23/00051, ISCIII, Spain; co-funded by the Fondo Europeo de Desarrollo Regional-FEDER); MAMS is supported by a PFIS predoctoral fellowship from the ISCIII (FI21/00003, ISCIII, Spain; co-funded by the Fondo Europeo de Desarrollo Regional-FEDER); and BRM is supported by the ‘Miguel Servet’ program (CP19/00098, ISCIII, Spain; co-funded by the Fondo Europeo de Desarrollo Regional-FEDER), Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Electrochemical immunoplatform for the quantification of epithelial extracellular vesicles applied to prostate cancer diagnosis

  • Felici, Emiliano
  • González-Martínez, Coral
  • Griñán, Teresa Valero
  • Gato-Zambrano, Sheila
  • Pereira, Sirley V.
  • Fernández-Baldo, Martín A.
  • Ortega-Sánchez, Francisco G.
The data that has been used is confidential., Prostate cancer (PCa) is the second most commonly diagnosed cancer in men worldwide, and its early detection is critical for improving patient outcomes through timely and effective treatment. In this work, we present the first electrochemical immunoplatform based on magnetic microbeads (MBs) for the determination of epithelial extracellular vesicles (EpEVs), which are emerging as promising biomarkers for PCa diagnosis and prognosis. The immunoplatform employs MBs functionalized with anti-EpCAM antibodies to selectively capture EpEVs, forming sandwich-type immune complexes that are detected via amperometry at disposable screen-printed carbon electrodes. The method demonstrated a detection limit of 0.4 ng μL-1 of EpEVs obtained from PC-3 cell line's culture, excellent reproducibility (coefficient of variation <5 %), and high selectivity against potential interferences. Comparative analysis with colorimetric immune-magnet ELISA test showed a strong correlation between the two methods, confirming the reliability of the proposed approach. Furthermore, the electrochemical platform provided better precision and a lower limit of detection than the immune magnet ELISA method, indicating its superior analytical performance. Clinical validation using patient samples revealed that the combination of EpEV detection with PSA levels significantly improves the sensitivity and specificity of PCa diagnosis. This novel immunoplatform represents a promising analytical tool for early detection and monitoring of PCa, with potential applications in personalized cancer management., Universidad Nacional de San Luis (PROICO 02–2220), Agencia Nacional de Promoción Científica y Tecnológica (PICT-2021-GRF-TI-00136). Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET) (PIP–11220200100033CO). Instituto de Salud Carlos III (ISCIII) (PI22_01275, CP23/00134, DTS23_00030). Universidad de Granada (P32/22/02)., Peer reviewed
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Big data and artificial intelligence applied to blood and CSF fluid biomarkers in multiple sclerosis

  • Comabella Lopez, Manuel
  • TUR, CARMEN
  • Arrambide, Georgina
Fluid biomarkers; Artificial intelligence; Multiple scleorsis, Biomarcadores de fluidos; Inteligencia artificial; Esclerosis múltiple, Biomarcadors de fluids; Intel·ligència artificial; Esclerosi múltiple, Artificial intelligence (AI) has meant a turning point in data analysis, allowing predictions of unseen outcomes with precedented levels of accuracy. In multiple sclerosis (MS), a chronic inflammatory-demyelinating condition of the central nervous system with a complex pathogenesis and potentially devastating consequences, AI-based models have shown promising preliminary results, especially when using neuroimaging data as model input or predictor variables. The application of AI-based methodologies to serum/blood and CSF biomarkers has been less explored, according to the literature, despite its great potential. In this review, we aimed to investigate and summarise the recent advances in AI methods applied to body fluid biomarkers in MS, highlighting the key features of the most representative studies, while illustrating their limitations and future directions., The author(s) declare financial support was received for the research, authorship, and/or publication of this article. CT is currently being funded by the Miguel Servet contract, awarded by the Instituto de Salud Carlos III (ISCIII), Spanish Ministry of Science and Innovation (award number: CP23/00117). She has also received research support from the ISCIII through the FORTALECE grant (FORT23/00034).
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Concurrence of FGFR1 mutations modulates oncogenesis in glioneuronal tumors

  • Boni, Jacopo
  • Fernández-González, Míriam
  • Han, HyeRim
  • Roca, Carla
  • Wong, Cassandra
  • Rioja, Cristina
  • Nogué i Ansón, Clara
  • MANEN-FREIXA, LETICIA
  • Boulais, Jonathan
  • Torres-Urtizberea, Endika
  • Gomez Moruno, Antonio
  • Hasselblatt, Martin
  • Estrada-Tejedor, Roger
  • Antolin, Albert A.
  • Elkholi, Islam
  • Jabado, Nada
  • Côté, Jean-François
  • Gingras, Anne-Claude
  • Rivera, Barbara
FGFR1 genetic alterations are associated with brain malignancies, including FGFR1 mutations in familial and sporadic cases of low-grade glioneuronal tumors, suggesting intrinsic mechanisms of selective pressure toward FGFR1 multiple events arising in the context of a quiet genome. To decipher the molecular mechanisms triggered by multiple concurrent FGFR1 mutations, we have mapped the proximal interactome of wild-type, single- and double-mutant FGFR1 proteins through a BioID-MS approach. Our data reveal novel oncogenic functionality for the two hotspot mutations N546K and K656E, linked to evasion of lysosomal degradation. Further, we identified a modulatory tumor-suppressive role for the susceptibility variant R661P, which hampers the oncogenic potential of both hotspot N546K and K656E mutations by rescuing receptor degradation and reducing N546K affinity for the downstream effector PLCγ. Introducing the R661P missense variant was sufficient to abolish self-renewal capacity of oligodendroglioma cells and downregulate genes involved in neurodevelopment and neuro-glial cell fate decisions, both aspects overcome in the double mutants. This study sheds light on contextual oncogenic effects associated with FGFR1 alterations and their recurrence in low-mutation burden and therapy naive tumors., info:eu-repo/semantics/publishedVersion
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

A data-driven model of disability progression in progressive multiple sclerosis

  • garbarino, sara
  • Lorenzi, Marco
  • Pardini, Matteo
  • PIANA, MICHELE
  • UCCELLI, Antonio
  • TUR, CARMEN
Bayesian learning; Multimodal data; Primary progressive multiple sclerosis, Aprendizaje bayesiano; Datos multimodales; Esclerosis múltiple progresiva primaria, Aprenentatge bayesià; Dades multimodals; Esclerosi múltiple progressiva primària, This study applies the Gaussian process progression model, a Bayesian data-driven disease progression model, to analyse the evolution of primary progressive multiple sclerosis. Utilizing data from 1521 primary progressive multiple sclerosis participants collected within the International Progressive Multiple Sclerosis Alliance Project, the analysis includes 18 581 longitudinal time-points (average follow-up time: 28.2 months) of disability assessments including the expanded disability status scale, symbol digit modalities, timed 25-foot-walk, 9-hole-peg test and of MRI metrics such as T1 and T2 lesion volume and normalized brain volume. From these data, Gaussian process progression model infers a data-driven description of the progression common to all individuals, alongside scores measuring the individual progression rates relative to the population, spanning ∼50 years of disease duration. Along this timeline, Gaussian process progression model identifies an initial steep worsening of the expanded disability status scale that stabilizes after ∼30 years of disease duration, suggesting its diminished utility in monitoring disease progression beyond this time. Conversely, it underscores the slower evolution of normalized brain volume across the disease duration. The individual progression rates estimated by Gaussian process progression model can be used to identify three distinct sub-groups within the primary progressive multiple sclerosis population: a normative group (76% of the population) and two ‘outlier’ sub-groups displaying either accelerated (13% of the population) or decelerated (11%) progression compared to the normative one. Notably, fast progressors exhibit older age at symptom onset (38.5 versus 35.0, P < 0.0001), a higher prevalence of males (61.1% versus 48.5%, P = 0.013) and a higher lesion volumes both in T1 (4.1 versus 0.6, P < 0.0001) and T2 (16.5 versus 7.9, P < 0.0001) compared to slow progressors. Prognostically, fast progressors demonstrate a significantly worse prognosis, with double the risk of experiencing a 3-month confirmed disease progression on expanded disability status scale compared to the normative population according to Cox proportional hazard modelling (HR = 2.09, 95% CI: 1.66–2.62, P < 0.0001) and a shorter median time from the onset of disease symptoms to reaching a confirmed expanded disability status scale 6 (95% CI: 5.83–7.68 years, P < 0.0001). External validation on a test set comprising 227 primary progressive multiple sclerosis participants from the SPI2 trial produced consistent results, with slow progressors exhibiting a reduced risk of experiencing 3-month confirmed disease progression determined through expanded disability status scale (HR = 0.21), while fast progressors facing an increased risk (HR = 1.45). This study contributes to our understanding of disability accrual in primary progressive multiple sclerosis, integrating diverse disability assessments and MRI measurements. Moreover, the identification of distinct sub-groups underscores the heterogeneity in progression rates among patients, offering invaluable insights for patient stratification and monitoring in clinical trials, potentially facilitating more targeted and personalized interventions., This investigation was supported by an award from the International Progressive Multiple Sclerosis Alliance (award reference number PA-1412-02420). This work was supported by #NEXTGENERATIONEU (NGEU) and funded by the Ministero dell’Università e delle Ricerca, Italy (MUR), National Recovery and Resilience Plan (NRRP), project MNESYS (PE0000006)—A Multiscale integrated approach to the study of the nervous system in health and disease (DN. 1553 11.10.2022). The authors acknowledge financial contribution from the Italian Ministry of Health, with the project NeuroArtP3 (NET-2018-12366666). S.G. acknowledges financial contributions from the Istituto Nazionale di Alta Matematica—Gruppo Nazionale di Calcolo Scientifico (INdAM–GNCS) Project (CUP_E53C22001930001). C.T. is currently being funded by a Miguel Servet contract, awarded by the Instituto de Salud Carlos III (ISCIII), Ministerio de Ciencia e Innovación de España (CP23/00117). She has also received a 2023 FORTALECE grant, awarded by the ISCIII (FORT23/00034) and a 2020 Junior Leader La Caixa Fellowship (fellowship code: LCF/BQ/PI20/11760008), awarded by ‘la Caixa’ Foundation (ID 100010434), a 2021 Merck’s Award for the Investigation in multiple sclerosis, awarded by Fundación Merck Salud (Spain), and a Research Grant awarded by the ISCIII, Ministerio de Ciencia e Innovación de España (PI21/01860). M.L. acknowledges funding from the Michael J. Fox Foundation for Parkinson’s Research (grant ID MJFF-021683). F.B. received the 2022 Biostatistic/Informatics Junior Faculty Award (grant code BI-2107-38160) awarded by the National Multiple Sclerosis Society.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Evaluation of magnetic resonance spectroscopy total sodium concentration measures, and associations with microstructure and physical impairment in cervical myelopathy

  • Solanky, Bhavana
  • Al-Ahmad, Selma
  • Yang, Xixi
  • Prados Carrasco, Ferran
  • TUR, CARMEN
  • Grussu, Francesco
Cervical myelopathy; Macromolecular tissue volume; Spinal cord, Mielopatia cervical; Volum del teixit macromolecular; Medul·la espinal, Mielopatía cervical; Volumen del tejido macromolecular; Médula espinal, Spinal cord injury causes a cascade of physiological responses, which may trigger a subsequent neurotoxic increase in intracellular sodium. This can lead to neurodegeneration, both at and beyond the site of injury, causing clinical symptoms and loss of function. However, in vivo measurements of tissue sodium remain challenging. Here we utilise sodium magnetic resonance spectroscopy (23Na-MRS) at 3T to measure tissue sodium concentration (TSC) and its association with microstructural measures and macromolecular MRI metrics in the cervical spinal cord, distal to the site of injury. Twenty people with cervical myelopathy and twenty healthy controls, were studied. Associations with motor and sensory impairments were explored using ASIA and jOAMEQ scores. No significant difference in TSC in the cervical myelopathy group (39 ± 10 mM) relative to healthy controls (35 ± 13 mM) was found. However, patients had a significantly lower cord-cross-sectional area than controls (70 ± 9 mm2 vs. 82 ± 9 mm2, p < 0.001). Lower-extremity function positively correlated with intracellular volume fraction (p = 0.031). In conclusion, using 23Na-MRS, TSC in cervical myelopathy patients was successfully measured. Differences in TSC relative to healthy controls did not reach significance, despite a significant reduction in cord-cross-sectional area. However, lower intracellular volume fraction, indicating reduced neurite density distal to the site of injury, was associated with physical impairment., This study was supported by Wings for Life (#169111) to CGWK and BS. CGWK receives funding from MRC (#MR/S026088/1), Ataxia UK, Rosetrees Trust (#PGL22/100041 and #PGL21/10079). JNP is supported in part by funding from the United Kingdom’s Department of Health NIHR University College London Hospitals Biomedical Research Centres funding scheme. BS is also supported by the Multiple Sclerosis Society (175). CT is currently being funded by a Miguel Servet contract, awarded by the Instituto de Salud Carlos III (ISCIII), Ministerio de Ciencia e Innovación de España (CP23/00117). FG receives the support of a fellowship from “la Caixa” Foundation (ID 100010434). The fellowship code is "LCF/BQ/PR22/11920010".
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publicación Artículo científico (JournalArticle)

Big data and artificial intelligence applied to blood and CSF fluid biomarkers in multiple sclerosis

  • Comabella Lopez, Manuel
  • TUR, CARMEN
  • Arrambide, Georgina
Fluid biomarkers; Artificial intelligence; Multiple scleorsis, Biomarcadores de fluidos; Inteligencia artificial; Esclerosis múltiple, Biomarcadors de fluids; Intel·ligència artificial; Esclerosi múltiple, Artificial intelligence (AI) has meant a turning point in data analysis, allowing predictions of unseen outcomes with precedented levels of accuracy. In multiple sclerosis (MS), a chronic inflammatory-demyelinating condition of the central nervous system with a complex pathogenesis and potentially devastating consequences, AI-based models have shown promising preliminary results, especially when using neuroimaging data as model input or predictor variables. The application of AI-based methodologies to serum/blood and CSF biomarkers has been less explored, according to the literature, despite its great potential. In this review, we aimed to investigate and summarise the recent advances in AI methods applied to body fluid biomarkers in MS, highlighting the key features of the most representative studies, while illustrating their limitations and future directions., The author(s) declare financial support was received for the research, authorship, and/or publication of this article. CT is currently being funded by the Miguel Servet contract, awarded by the Instituto de Salud Carlos III (ISCIII), Spanish Ministry of Science and Innovation (award number: CP23/00117). She has also received research support from the ISCIII through the FORTALECE grant (FORT23/00034).
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publicación Artículo científico (JournalArticle)

A data-driven model of disability progression in progressive multiple sclerosis

  • garbarino, sara
  • Lorenzi, Marco
  • Pardini, Matteo
  • PIANA, MICHELE
  • UCCELLI, Antonio
  • TUR, CARMEN
Bayesian learning; Multimodal data; Primary progressive multiple sclerosis, Aprendizaje bayesiano; Datos multimodales; Esclerosis múltiple progresiva primaria, Aprenentatge bayesià; Dades multimodals; Esclerosi múltiple progressiva primària, This study applies the Gaussian process progression model, a Bayesian data-driven disease progression model, to analyse the evolution of primary progressive multiple sclerosis. Utilizing data from 1521 primary progressive multiple sclerosis participants collected within the International Progressive Multiple Sclerosis Alliance Project, the analysis includes 18 581 longitudinal time-points (average follow-up time: 28.2 months) of disability assessments including the expanded disability status scale, symbol digit modalities, timed 25-foot-walk, 9-hole-peg test and of MRI metrics such as T1 and T2 lesion volume and normalized brain volume. From these data, Gaussian process progression model infers a data-driven description of the progression common to all individuals, alongside scores measuring the individual progression rates relative to the population, spanning ∼50 years of disease duration. Along this timeline, Gaussian process progression model identifies an initial steep worsening of the expanded disability status scale that stabilizes after ∼30 years of disease duration, suggesting its diminished utility in monitoring disease progression beyond this time. Conversely, it underscores the slower evolution of normalized brain volume across the disease duration. The individual progression rates estimated by Gaussian process progression model can be used to identify three distinct sub-groups within the primary progressive multiple sclerosis population: a normative group (76% of the population) and two ‘outlier’ sub-groups displaying either accelerated (13% of the population) or decelerated (11%) progression compared to the normative one. Notably, fast progressors exhibit older age at symptom onset (38.5 versus 35.0, P < 0.0001), a higher prevalence of males (61.1% versus 48.5%, P = 0.013) and a higher lesion volumes both in T1 (4.1 versus 0.6, P < 0.0001) and T2 (16.5 versus 7.9, P < 0.0001) compared to slow progressors. Prognostically, fast progressors demonstrate a significantly worse prognosis, with double the risk of experiencing a 3-month confirmed disease progression on expanded disability status scale compared to the normative population according to Cox proportional hazard modelling (HR = 2.09, 95% CI: 1.66–2.62, P < 0.0001) and a shorter median time from the onset of disease symptoms to reaching a confirmed expanded disability status scale 6 (95% CI: 5.83–7.68 years, P < 0.0001). External validation on a test set comprising 227 primary progressive multiple sclerosis participants from the SPI2 trial produced consistent results, with slow progressors exhibiting a reduced risk of experiencing 3-month confirmed disease progression determined through expanded disability status scale (HR = 0.21), while fast progressors facing an increased risk (HR = 1.45). This study contributes to our understanding of disability accrual in primary progressive multiple sclerosis, integrating diverse disability assessments and MRI measurements. Moreover, the identification of distinct sub-groups underscores the heterogeneity in progression rates among patients, offering invaluable insights for patient stratification and monitoring in clinical trials, potentially facilitating more targeted and personalized interventions., This investigation was supported by an award from the International Progressive Multiple Sclerosis Alliance (award reference number PA-1412-02420). This work was supported by #NEXTGENERATIONEU (NGEU) and funded by the Ministero dell’Università e delle Ricerca, Italy (MUR), National Recovery and Resilience Plan (NRRP), project MNESYS (PE0000006)—A Multiscale integrated approach to the study of the nervous system in health and disease (DN. 1553 11.10.2022). The authors acknowledge financial contribution from the Italian Ministry of Health, with the project NeuroArtP3 (NET-2018-12366666). S.G. acknowledges financial contributions from the Istituto Nazionale di Alta Matematica—Gruppo Nazionale di Calcolo Scientifico (INdAM–GNCS) Project (CUP_E53C22001930001). C.T. is currently being funded by a Miguel Servet contract, awarded by the Instituto de Salud Carlos III (ISCIII), Ministerio de Ciencia e Innovación de España (CP23/00117). She has also received a 2023 FORTALECE grant, awarded by the ISCIII (FORT23/00034) and a 2020 Junior Leader La Caixa Fellowship (fellowship code: LCF/BQ/PI20/11760008), awarded by ‘la Caixa’ Foundation (ID 100010434), a 2021 Merck’s Award for the Investigation in multiple sclerosis, awarded by Fundación Merck Salud (Spain), and a Research Grant awarded by the ISCIII, Ministerio de Ciencia e Innovación de España (PI21/01860). M.L. acknowledges funding from the Michael J. Fox Foundation for Parkinson’s Research (grant ID MJFF-021683). F.B. received the 2022 Biostatistic/Informatics Junior Faculty Award (grant code BI-2107-38160) awarded by the National Multiple Sclerosis Society.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publicación Artículo científico (JournalArticle)

Evaluation of magnetic resonance spectroscopy total sodium concentration measures, and associations with microstructure and physical impairment in cervical myelopathy

  • Solanky, Bhavana
  • Al-Ahmad, Selma
  • Yang, Xixi
  • Prados Carrasco, Ferran
  • TUR, CARMEN
  • Grussu, Francesco
Cervical myelopathy; Macromolecular tissue volume; Spinal cord, Mielopatia cervical; Volum del teixit macromolecular; Medul·la espinal, Mielopatía cervical; Volumen del tejido macromolecular; Médula espinal, Spinal cord injury causes a cascade of physiological responses, which may trigger a subsequent neurotoxic increase in intracellular sodium. This can lead to neurodegeneration, both at and beyond the site of injury, causing clinical symptoms and loss of function. However, in vivo measurements of tissue sodium remain challenging. Here we utilise sodium magnetic resonance spectroscopy (23Na-MRS) at 3T to measure tissue sodium concentration (TSC) and its association with microstructural measures and macromolecular MRI metrics in the cervical spinal cord, distal to the site of injury. Twenty people with cervical myelopathy and twenty healthy controls, were studied. Associations with motor and sensory impairments were explored using ASIA and jOAMEQ scores. No significant difference in TSC in the cervical myelopathy group (39 ± 10 mM) relative to healthy controls (35 ± 13 mM) was found. However, patients had a significantly lower cord-cross-sectional area than controls (70 ± 9 mm2 vs. 82 ± 9 mm2, p < 0.001). Lower-extremity function positively correlated with intracellular volume fraction (p = 0.031). In conclusion, using 23Na-MRS, TSC in cervical myelopathy patients was successfully measured. Differences in TSC relative to healthy controls did not reach significance, despite a significant reduction in cord-cross-sectional area. However, lower intracellular volume fraction, indicating reduced neurite density distal to the site of injury, was associated with physical impairment., This study was supported by Wings for Life (#169111) to CGWK and BS. CGWK receives funding from MRC (#MR/S026088/1), Ataxia UK, Rosetrees Trust (#PGL22/100041 and #PGL21/10079). JNP is supported in part by funding from the United Kingdom’s Department of Health NIHR University College London Hospitals Biomedical Research Centres funding scheme. BS is also supported by the Multiple Sclerosis Society (175). CT is currently being funded by a Miguel Servet contract, awarded by the Instituto de Salud Carlos III (ISCIII), Ministerio de Ciencia e Innovación de España (CP23/00117). FG receives the support of a fellowship from “la Caixa” Foundation (ID 100010434). The fellowship code is "LCF/BQ/PR22/11920010".
e_Buah Biblioteca Digital Universidad de Alcalá
Publicación Artículo científico (JournalArticle)

Prevalence and risk factors of active hepatitis C infection among at-risk migrant populations in Madrid, Spain, 2019 to 2023

  • Ryan Murúa, Pablo
  • Valencia la Rosa, Jorge Antonio
  • Pérez García, Felipe|||0000-0002-4885-4334
  • Quero Delgado, Marta
  • Cuevas, Guillermo
  • Manzano, Samuel
  • Estévez, Samuel
  • Martínez, Isidoro
  • Sepúlveda Crespo, Daniel
  • Resino, Salvador
11 p., Background: Hepatitis C virus (HCV) microelimination among at-risk migrants supports global elimination goals. Aim: To evaluate risk factors, prevalence and trends of active HCV infection among at-risk migrants screened for HCV in Madrid from 2019-23. Methods: At-risk migrants (born outside Spain, living in country < 10 years regardless of legal status), were screened for HCV via mobile units with rapid antibody testing, and confirmed by RNA testing. Recruitment of this convenience sample focused on migrant centres, shelters, harm reduction centres and social service sites. Primary outcome was active HCV prevalence. Risk factors analysed included origin, alcohol use, no stable income, drug use and sexual behaviour. Data were analysed using general linear models with negative binomial distribution and p values adjusted for multiple comparisons (q values). Results: Among 2,288 migrants, 6.5% (149/2,288) had anti-HCV antibodies, 47.0% (70/149) of whom tested positive for HCV-RNA; 81.4% (57/70) began antiviral therapy. Overall prevalence of active HCV infection was 3.1% (70/2,288). Injection drug use (non-active vs never used ((aIRR: 7.3; 95% CI:2.7-12.7) and active (aIRR:14.7; 95% CI:6.7-32.1)), European origin (vs non-European; aIRR:5.8; 95% CI: 2.7-12.7) and alcohol misuse (vs no misuse; aIRR: 1.8; 95% CI: 1.1-2.9) were main risk factors. Prevalence showed no significant change during 2019-23 in the overall population and across risk groups. Conclusion: At-risk migrants screened in Madrid had a high prevalence of active HCV infection. This is higher than reported estimates for the general Spanish population and supports the need to enhance targeted HCV prevention, screening and treatment strategies among migrant populations., Gilead Sciences, Instituto de Salud Carlos III, Asociación Española para el Estudio del Hígado, Consorcio Centro de Investigación Biomédica en Red, Ministerio de Ciencia e Innovación, Unión Europea, Madrid Positivo Association
e_Buah Biblioteca Digital Universidad de Alcalá
Publicación Artículo científico (JournalArticle)

Challenges in accurate HDV RNA quantification: inter-assay variability and the impact of thermal shock

  • Pérez García, Felipe|||0000-0002-4885-4334
  • Virseda Berdices, Ana
  • Pita Martínez, Carlos
  • Muñoz Monte, Mario
  • Sepúlveda Crespo, Daniel
  • Codina, Helena
  • Alonso, Roberto
  • Mesones, Lara
  • Rodrigo, Sandra
  • Macías, Juan Antonio
  • Real, Luis Miguel
  • Cuadros González, Juan|||0000-0003-4098-4377
  • Martínez, Isidoro
  • Resino, Salvador
11 p., Quantitative RT-PCR (qRT-PCR) is essential for monitoring hepatitis delta virus (HDV) RNA, yet assays lack standardization. We aimed to evaluate the performance of three qRT-PCR assays and to assess the impact of a pre-analytical thermal shock procedure. We conducted a comparative study using 206 samples (106 with anti-HDV antibodies and 100 anti-HDV-negative as a control group), which were tested in parallel with three qRT-PCR assays: Vircell, Certest, and Altona. Performance was evaluated for inter-assay agreement (kappa index), quantitative correlation (R²), and bias (BlandAltman). Altona detected 56 HDV-RNA positive samples, whereas Vircell and Certest detected 55 positive samples. Inter-assay agreement was perfect comparing Vircell vs Certest (agreement = 100%, к = 1.000) and almost perfect comparing Altona with both Vircell and Certest (agreement = 99.5%, к = 0.988). Quantitatively, Vircell and Certest assays showed relevant systematic biases compared to Altona, overestimating viral loads by approximately 0.24 log10 International Units (IU)/mL (Certest) and 0.33 log10 IU/mL (Vircell). The correlation with Altona was strong for Certest (R² = 0.864) and moderate for Vircell (R² = 0.793), while the correlation between Certest and Vircell was weaker (R² = 0.720). Thermal shock improved sensitivity in one case (Certest vs Vircell) but increased quantitative variability, worsening the inter-assay correlation (R² = 0.684). In conclusion, all three assays were highly concordant for the qualitative diagnosis of HDV infection, but their quantitative biases prevent their interchangeable use for treatment monitoring. Thermal shock is not recommended for routine monitoring, as a significant compromise in quantitative accuracy and precision outweighs any potential gains in sensitivity., European Society of Clinical Microbiology and Infectious Diseases, Instituto de Salud Carlos III, Centro de Investigación en Red en Enfermedades Infecciosas, Fundación para la Investigación Biomédica del Hospital Universitario Príncipe de Asturias